During the last session, Biofrontera Inc (NASDAQ:BFRI)’s traded shares were 132.34 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $1.23, reflecting an intraday gain of 31.71% or $0.3. The 52-week high for the BFRI share is $5.28, that puts it down -329.27 from that peak though still a striking 50.41% gain since the share price plummeted to a 52-week low of $0.61. The company’s market capitalization is $6.82M, and the average intraday trading volume over the past 10 days was 13.65 million shares, and the average trade volume was 405.62K shares over the past three months.
Biofrontera Inc (BFRI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. BFRI has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.83.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Biofrontera Inc (NASDAQ:BFRI) trade information
Biofrontera Inc (BFRI) registered a 31.71% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 31.71% in intraday trading to $1.23, hitting a weekly high. The stock’s 5-day price performance is 26.80%, and it has moved by 14.95% in 30 days. Based on these gigs, the overall price performance for the year is -73.83%. The short interest in Biofrontera Inc (NASDAQ:BFRI) is 0.47 million shares and it means that shorts have 0.82 day(s) to cover.
Biofrontera Inc (BFRI) estimates and forecasts
Statistics show that Biofrontera Inc has outperformed its competitors in share price, compared to the industry in which it operates. Biofrontera Inc (BFRI) shares have gone down -31.28% during the last six months, with a year-to-date growth rate more than the industry average at 81.51% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 82.10% this quarter and then drop -106.10% in the quarter after that. In the rating firms’ projections, revenue will increase 16.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.01M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 14.05M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 8.9M and 10.6M respectively. In this case, analysts expect current quarter sales to grow by 12.50% and then jump by 32.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 7.90%. While earnings are projected to return 75.31% in 2024.
BFRI Dividends
Biofrontera Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Biofrontera Inc (NASDAQ:BFRI)’s Major holders
Biofrontera Inc insiders own 32.06% of total outstanding shares while institutional holders control 35.86%, with the float percentage being 52.78%.
